BridgeBio Oncology Therapeutics, Inc. (BBOT) stock
BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.14−0.21 (-8.94%)
Close on Nov 13, 2026Market cap $171.57MP/E –Yield –
BridgeBio Oncology Therapeutics cash
Cash and short-term investments held at the end of each period.
BridgeBio Oncology Therapeutics's cash was $315.30M at Sep 30, 2026. For fiscal 2025 it was $425.50M, up 173.2% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $425.50M | +173.2% |
| FY2024 | Dec 31, 2024 | $155.76M | +62205.2% |
| FY2023 | Dec 31, 2023 | $250.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $315.30M | -32.7% |
| Q2 FY2026 | Jun 30, 2026 | $344.10M | +987.2% |
| Q1 FY2026 | Mar 31, 2026 | $388.90M | +1376.0% |
| Q4 FY2025 | Dec 31, 2025 | $425.50M | +173.2% |
| Q3 FY2025 | Sep 30, 2025 | $468.30M | +2194.5% |
| Q2 FY2025 | Jun 30, 2025 | $31.65M | +1644.3% |
| Q1 FY2025 | Mar 31, 2025 | $26.35M | +1329.2% |
| Q4 FY2024 | Dec 31, 2024 | $155.76M | +62205.2% |
| Q3 FY2024 | Sep 30, 2024 | $20.41M | – |
| Q2 FY2024 | Jun 30, 2024 | $1.81M | – |
| Q1 FY2024 | Mar 31, 2024 | $1.84M | – |
| Q4 FY2023 | Dec 31, 2023 | $250.00K | – |
See a number that looks wrong?